PDS Biotechnology (PDSB) Cash from Financing Activities (2014 - 2025)

PDS Biotechnology (PDSB) has 12 years of Cash from Financing Activities data on file, last reported at $4.2 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 2340.07% year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.8 million (down 36.72% YoY) and the FY2025 annual result came in at $12.8 million, down 36.72% from the prior year.
• Cash from Financing Activities advanced to $4.2 million in Q4 2025, from $241205.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $48.8 million in Q2 2021 to a low of -$13786.0 in Q2 2024.
• A 5-year average of $7.0 million and a median of $802326.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 74666484.62% — and 2024, when it tumbled 105.74%.
• Tracing PDSB's Cash from Financing Activities over 5 years: stood at $13.0 in 2021, then soared by 74666484.62% to $9.7 million in 2022, then advanced by 10.92% to $10.8 million in 2023, then tumbled by 98.4% to $172778.0 in 2024, then soared by 2340.07% to $4.2 million in 2025.
• The last three Cash from Financing Activities figures came in at $4.2 million (Q4 2025), $241205.0 (Q3 2025), and $995944.0 (Q2 2025), per Business Quant data.